At 9–12 weeks after disease onset, participants who had initially severe COVID-19 tended to have significantly higher levels of IP10 and sCD163 and lower levels of IL10, IL6, TNFα, IL17 and IL13 (Fig 2) compared to those with mild or moderate disease, when adjusting for other covariates. The gene discussed is IL10; the disease is COVID-19.